Tower Research Capital (TRC)’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-8,488
| Closed | -$74K | – | 4597 |
|
|
2018
Q2 | $74K | Buy |
8,488
+5,692
| +204% | +$51.2K | ﹤0.01% | 1625 |
|
|
2018
Q1 | $28K | Sell |
2,796
-329
| -11% | -$2.76K | ﹤0.01% | 2008 |
|
|
2017
Q4 | $15K | Buy |
3,125
+151
| +5% | +$734 | ﹤0.01% | 2301 |
|
|
2017
Q3 | $14K | Buy |
2,974
+2,414
| +431% | +$11.3K | ﹤0.01% | 2939 |
|
|
2017
Q2 | $3K | Buy |
560
+396
| +241% | +$1.77K | ﹤0.01% | 2293 |
|
|
2017
Q1 | $1K | Buy |
+164
| New | +$828 | ﹤0.01% | 2929 |
|
|
2016
Q3 | – | Sell |
-931
| Closed | -$7K | – | 5014 |
|
|
2016
Q2 | $7K | Sell |
931
-3,051
| -77% | -$21.5K | ﹤0.01% | 3208 |
|
|
2016
Q1 | $27K | Buy |
3,982
+1,823
| +84% | +$13.4K | ﹤0.01% | 1151 |
|
|
2015
Q4 | $22K | Buy |
2,159
+2,086
| +2,858% | +$24.2K | ﹤0.01% | 1226 |
|
|
2015
Q3 | $1K | Sell |
73
-958
| -93% | -$10.6K | ﹤0.01% | 3781 |
|
|
2015
Q2 | $9K | Buy |
1,031
+931
| +931% | +$7.03K | ﹤0.01% | 2847 |
|
|
2015
Q1 | $1K | Sell |
100
-1,333
| -93% | -$8.25K | ﹤0.01% | 4238 |
|
|
2014
Q4 | $8K | Buy |
+1,433
| New | +$8.34K | ﹤0.01% | 2388 |
|
|
2014
Q2 | – | Sell |
-1,436
| Closed | -$10K | – | 4967 |
|
|
2014
Q1 | $10K | Buy |
1,436
+1,318
| +1,117% | +$9.11K | ﹤0.01% | 2644 |
|
|
2013
Q4 | $1K | Sell |
118
-898
| -88% | -$6.12K | ﹤0.01% | 4310 |
|
|
2013
Q3 | $7K | Buy |
+1,016
| New | +$6.84K | ﹤0.01% | 3491 |
|
Tower Research Capital (TRC)'s JNP Position: Q3 2018 in Review
Tower Research Capital (TRC) sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 8,488 shares — an estimated $74K sold.
Tower Research Capital (TRC) first reported a position in JNP in Q3 2013 and held it in 16 quarters. The position peaked at $74K in Q2 2018. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.
- Tower Research Capital (TRC) reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
- Tower Research Capital (TRC) sold 8,488 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $74K.
- Tower Research Capital (TRC) first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q3 2013 and held it in 16 quarters.
- Tower Research Capital (TRC)'s Juniper Pharmaceuticals, Inc. Common Stock position peaked at $74K in Q2 2018.
- 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2018, filed 13 Nov 2018.